Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06955169 · ClinicalTrials.gov registry record · Phase 2
Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
A Phase 2 study of Intracranial Meningioma, sponsored by RTOG Foundation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 153
- Enrollment target
- 3
- Study locations
NCT06955169: Recruiting Phase 2 study of Intracranial Meningioma, sponsored by RTOG Foundation.
NCT06955169 is a Phase 2 study of Intracranial Meningioma that is actively recruiting participants, run by RTOG Foundation. The registered enrollment target is 153 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (15% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06955169, a Phase 2 study of Intracranial Meningioma, is actively recruiting participants, sponsored by RTOG Foundation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 153 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is an open-label, multicenter, randomized, phase 2 clinical study to evaluate the efficacy of \[177Lu\]Lu-DOTATATE in patients with progressive grade 1-3 intracranial meningioma.
Primary Outcome
PFS defined as the time from randomization to date of disease progression per current RANO meningioma criteria or death, whichever occurs first
Conditions Studied
Interventions
- DRUG [177Lu]Lu-DOTATATE
- OTHER Standard of Care treatments
Study Locations (3)
Florida
- Baptist Health Medical Group Oncology - Miami
Georgia
- Piedmont Healthcare - Atlanta
Indiana
- Indiana University - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2025-12-24 |
| Est. Completion | 2030-08 |
| Phase | Phase 2 |
What NCT06955169 shows while recruiting
NCT06955169 is an interventional study that assigns participants to a tested intervention. The registered 153 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (15% higher).
The record links to 1 condition, with Intracranial Meningioma appearing as the primary indexed condition, and to 2 interventions - of which [177Lu]Lu-DOTATATE is the first listed.
NCT06955169 reports a single indexed study location in Florida, Georgia, Indiana.
Frequently Asked Questions
What is clinical trial NCT06955169 about?
NCT06955169 is a clinical study titled "Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment". This is an open-label, multicenter, randomized, phase 2 clinical study to evaluate the efficacy of \[177Lu\]Lu-DOTATATE in patients with progressive grade 1-3 intracranial meningioma.
What is the current status of trial NCT06955169?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 153 participants. The study started on 2025-12-24. Estimated completion is 2030-08.
What conditions does trial NCT06955169 study?
This clinical trial studies the following conditions: Intracranial Meningioma.
What interventions are being tested in trial NCT06955169?
The interventions under investigation include: [177Lu]Lu-DOTATATE (DRUG), Standard of Care treatments (OTHER).
Who is sponsoring clinical trial NCT06955169?
This trial is sponsored by RTOG Foundation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06955169 being conducted?
This trial has 3 study locations across Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intracranial Meningioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06955169's enrollment target sits among peer trials
153 449th of 2000 higher than 1,549 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283265 · 153 participants · NA
Neurophysiological Mechanisms of Language Comprehension
- NCT05554393 · 153 participants · Phase 2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- NCT05584501 · 153 participants · NA
ETE Interventions in the Dental Setting
- NCT05714839 · 153 participants · Phase 1
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI